<DOC>
	<DOCNO>NCT02364999</DOCNO>
	<brief_summary>This multinational , double-blind , randomize , parallel-group Phase 3 clinical trial evaluate efficacy safety bevacizumab-Pfizer plus paclitaxel carboplatin versus bevacizumab-EU plus paclitaxel carboplatin first-line treatment patient advance ( unresectable , locally advanced , recurrent metastatic ) non-squamous NSCLC .</brief_summary>
	<brief_title>A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Male female patient age least 18 year age , age consent region . Newly diagnose Stage IIIB IV nonsmall cell lung cancer ( accord Revised International System Staging Lung Cancer criterion 2010 ) recurrent nonsmall cell lung cancer ( NSCLC ) . Histologically cytologically confirm diagnosis predominately nonsquamous NSCLC . Be eligible receive study treatment bevacizumab , paclitaxel , carboplatin base local standard care , treatment advance metastatic nonsquamous NSCLC . Small cell lung cancer ( SCLC ) combination SCLC NSCLC . Squamouscell tumor mix adenosquamous carcinoma predominantly squamous nature . Evidence tumor compress invade major blood vessel tumor cavitation likely bleed . Known sensitize EGFR mutation ( example , deletion 19 L858R ) EML4ALK translocation positive mutation . Prior systemic therapy NSCLC ; prior neoadjuvant adjuvant therapy allow surgical resection primary disease perform .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>